Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
02 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/prolynx-announces-publication-of-its-once-monthly-semaglutide-in-the-proceedings-of-the-national-academy-of-sciences-302318520.html
21 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/21/2933785/30541/en/ProLynx-announces-preclinical-results-of-long-acting-semaglutide-requiring-once-monthly-dosing.html
25 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/03/25/2851654/30541/en/ProLynx-announces-initiation-of-the-Phase-II-Topology-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-triple-negative-breast-cancer-at-the-Institut-Curie.html
05 Feb 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/02/05/2823569/30541/en/ProLynx-announces-initiation-of-Phase-I-II-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-patients-with-rare-CNS-tumors-at-the-National-Cancer-Institute-NCI.html
https://www.globenewswire.com//news-release/2024/01/24/2815405/30541/en/ProLynx-announces-a-publication-proposing-that-a-long-acting-prodrug-of-SN-38-could-be-effective-in-treating-Sacituzumab-Govitecan-Resistant-Tumors.html
07 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/07/2530299/30541/en/ProLynx-announces-initiation-of-Phase-II-clinical-trial-of-its-DNA-damaging-agent-PLX038-in-patients-with-platinum-resistant-Ovarian-Cancer-at-the-Mayo-Clinic.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?